Yifeng Pharmary(SH:603939) Xin Lang Cai Jing·2025-08-29 01:52Core Insights - Yifeng Pharmacy (603939.SH) reported a total operating revenue of 11.722 billion yuan for the first half of 2025, a decrease of 40.5815 million yuan compared to the same period last year, representing a year-on-year decline of 0.35% [1] - The net profit attributable to shareholders was 880 million yuan, while the net cash inflow from operating activities was 1.57 billion yuan, down 252 million yuan from the same period last year, reflecting a year-on-year decrease of 13.84% [1] Financial Metrics - The latest debt-to-asset ratio stands at 54.84% [3] - The latest gross profit margin is 40.47%, and the return on equity (ROE) is 7.89% [4] - The diluted earnings per share (EPS) is 0.73 yuan [4] - The total asset turnover ratio is 0.43 times, ranking 18th among disclosed peers, a decrease of 0.03 times year-on-year, which is a decline of 7.18% [4] - The inventory turnover ratio is 1.59 times, ranking 21st among disclosed peers, down 0.27 times year-on-year, reflecting a decline of 14.43% [4] Shareholder Structure - The number of shareholders is 21,600, with the top eight shareholders holding a total of 683 million shares, accounting for 56.30% of the total share capital [4] - The top shareholders include: 1. Ningbo Meishan Free Trade Port Area Houxin Venture Capital Partnership (Limited Partnership) - 21.6% 2. Hong Kong Central Clearing Limited - 19.5% 3. Gao Yi - 11.6% 4. Ningbo Meishan Free Trade Port Area Yizhi Feng Enterprise Management Partnership (Limited Partnership) - 1.05% 5. Agricultural Bank of China Co., Ltd. - CSI 500 ETF - 0.74% 6. Industrial and Commercial Bank of China Co., Ltd. - China Europe Medical Health Mixed Securities Investment Fund - 0.64% 7. Han Hongchang - 0.50% 8. Ningbo Meishan Free Trade Port Area Yirentang Enterprise Management Partnership (Limited Partnership) - 0.48% [4]